The strong profitability inflection and raised guidance confirm the growth narrative, but the stock's historically low model win rate (20% T+20) suggests caution on near-term momentum. Monitor the BoxX-NoAF and LeAAPS clinical trial readouts as additional catalysts. The raised guidance supports a positive longer-term view.
Price Chart
Executive Summary
AtriCure reported Q2 2026 results with a massive EPS beat of $0.18 vs $0.03 consensus (+500%), revenue of $153.6M (+12.8% YoY) and a swing to net income of $9.0M from a loss last year. The company raised full-year revenue guidance to $602M-$610M and adjusted EBITDA guidance to $85M-$89M, signaling accelerating profitability.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $153.6M, +12.8% YoY (12.4% constant currency)
- GAAP EPS $0.18 vs $0.03 consensus (500% beat)
- Net income $9.0M vs loss of $6.2M in Q2 2025
- Gross margin 77.2%, +269 bps YoY
- Adjusted EBITDA $27.3M, +78% YoY
- Full-year 2026 revenue guidance raised to $602M-$610M (from $600M-$610M)
- Full-year adjusted EBITDA guidance raised to $85M-$89M (from $80M-$82M)
- Full-year adjusted EPS guidance initiated at $0.24-$0.32
- Cash generation of $21.6M in Q2
Financial Impact
EPS beat by 500% ($0.18 vs $0.03), revenue growth 12.8% YoY, guidance raised across all metrics
Risk Factors
- Clinical trial data readouts (BoxX-NoAF, LeAAPS) are binary and could reverse sentiment
- Competition from catheter-based technologies and drugs
- Reliance on FDA approvals and reimbursement for new products
- Elevated share-based compensation ($12.3M in Q2) dilutes earnings
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001323885-26-000032 |
| Document: atrc-20260723.htm | 0001323885-26-000032 |
| Document: 0001323885-26-000032-index-headers.html | 0001323885-26-000032 |
| Document: 0001323885-26-000032-index.html | 0001323885-26-000032 |
| Document: 0001323885-26-000032.txt | 0001323885-26-000032 |
| 8-K Data (Synthetic) | 0001323885-26-000032 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | Insider Cluster | $55.79 $58.32 | ▲ +4.53% | ▲ +2.88% | $55.14 (−1.17%) |
Aug 7, 2026 8w ago | Insider Cluster | $41.39 $44.30 | ▲ +7.03% | ▲ +6.63% | $55.14 (+33.22%) |
Jul 30, 2026 9w ago | Insider Cluster | $40.15 $39.49 | ▼ −1.64% | ▼ −5.27% | $55.14 (+37.33%) |
Jul 30, 2026 9w ago | Insider Cluster | $40.15 $39.49 | ▼ −1.64% | ▼ −5.27% | $55.14 (+37.33%) |
Jul 23, 2026 10w ago | 8-K | $35.04 $40.15 | ▲ +14.58% | ▲ +14.21% | $55.14 (+57.36%) |
Jun 14, 2026 15w ago | Institutional Cluster | $27.98 $28.44 | ▲ +1.64% | ▲ +3.03% | $55.14 (+97.07%) |
Jun 11, 2026 16w ago | Institutional Cluster | $28.41 $27.12 | ▲ +4.54% | ▲ +4.97% | $55.14 (−94.09%) |
May 22, 2026 19w ago | Insider Cluster | $28.29 $26.48 | ▼ −6.40% | ▼ −8.07% | $55.14 (+94.91%) |
May 5, 2026 21w ago | 8-K | $28.01 $26.69 | ▼ −4.71% | ▼ −5.84% | $55.14 (+96.86%) |
Apr 6, 2026 25w ago | DEFA14A | $29.19 $28.66 | ▼ −1.82% | ▼ −5.95% | $55.14 (+88.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access